International project develops heart device suited to Japanese market:
This article was originally published in Clinica
Executive Summary
Each year, 2,000-3,000 Japanese patients require artificial hearts, but are unable to acquire one due to the high cost and large size of conventional pumps, which are unsuitable for many Japanese people. Recently, the Tokyo Women's Medical University (in liaison with researchers from Waseda University, Sun Medical Technology Research and the US University of Pittsburgh) successfully implanted a small-sized blood pump, reports Asahi Shimbun. The Evaheart is 420 grams, which means it can be used in smaller women and children. The device costs around Y5m ($46,000), which is less than half the price of foreign pumps. It is hoped that the new pump will encourage more manufacturing of implant devices in Japan.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.